Other trials examining the antidepressant effect of repurposed anti-hyperglycemic (anti-diabetic) agents including the insulin sensitizing agent pioglitazone [32] and glucagon-like peptide-1 (GLP-1) receptor agonists [33,34] also suggest that the attenuation of insulin resistance could be a plausible target for the treatment of depression. Here, GLP1R is linked to depressive disorder.